R Anthony Williamson

This inventor holds 11 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Scripps Research Institute, University of California, Other. Active years: 1998-2011.

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 45.5

EPO Patents = 1

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 122(Granted Patents)

Location History:

Del Mar, CA (US) (2002 - 2006)
San Diego, CA (US) (1998 - 2011)

Company Filing History:

8 out of 1,204

Scripps Research Institute

patents

4 out of 15,977

University of California

patents

3 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2011

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7939641 - Motif-grafted hybrid polypeptides and uses thereof (2011-05-10),

2. 7094553 - Antibodies specific for ungulate PrP (2006-08-22),

3. 7060799 - Antibody for ligand capture assay (2006-06-13),

4. 7052675 - [object Object] (2006-05-30),

5. 6858397 - Antibodies specific for native PrPsc (2005-02-22),

6. 6562341 - Antibodies specific for native PrPSc (2003-05-13),

7. 6537548 - Antibodies specific for ungulate PrP (2003-03-25),

8. 6376170 - Ligand capture-directed selection of antibody (2002-04-23),

9. 6372214 - Antibodies specific for native PrPSc (2002-04-16),

10. 6290954 - Antibodies specific for native PrPSc (2001-09-18),

11. 5846533 - Antibodies specific for native PrP.sup.Sc (1998-12-08),

Title: R Anthony Williamson: Innovator in Hybrid Polypeptides

Introduction

R Anthony Williamson is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of hybrid polypeptides. With a total of 11 patents, Williamson has made strides in developing innovative solutions for diseases associated with protein aggregation.

Latest Patents

Williamson's latest patents include groundbreaking work on motif-grafted hybrid polypeptides and their applications. These hybrid polypeptides are designed to specifically bind to disease-associated isoforms of polypeptides involved in protein aggregation diseases. One notable embodiment of his work includes a hybrid protein that targets the infectious form of a prion (PrP). Additionally, he has developed antibodies that exhibit a high degree of binding affinity to native and denatured ungulate PrP, which can be utilized in assays to determine prion infections in samples.

Career Highlights

Throughout his career, Williamson has been associated with esteemed institutions such as The Scripps Research Institute and the University of California. His work has not only advanced scientific understanding but has also paved the way for potential diagnostic and therapeutic applications in the medical field.

Collaborations

Williamson has collaborated with notable figures in the scientific community, including Dennis R Burton and Stanley B Prusiner. These collaborations have further enriched his research and contributed to the advancement of knowledge in his area of expertise.

Conclusion

R Anthony Williamson's innovative work in hybrid polypeptides exemplifies the impact of dedicated research on addressing complex medical challenges. His contributions continue to influence the field and hold promise for future advancements in disease diagnosis and treatment.